RxDoctor Payments Data

Rebecca Lolley, MD

Cardiovascular Disease · Greeley, CONPI 1518375427

Payments from drug & device makers

$721in general payments, 2019–2025

Across 25 payments — averaging $28.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$267
  • Pfizer$105
  • Novo Nordisk$98
  • Amgen$83
  • Novartis$38
  • Philips North America LLC$33
  • plus $97 from 5 others

What the payments were for

  • Food & beverage$721100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$721 in reported general payments places this provider in the 35th percentile of 276 cardiovascular disease providers in Colorado.

See all cardiovascular disease providers in Colorado

Medicare billing

Part B allowed, 2024
$66,299
Medicare patients
353
Services billed
683

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban152$153,227
XareltoRivaroxaban90$106,089
EntrestoSacubitril/Valsartan45$38,959
Repatha SureclickEvolocumab24$34,508
Repatha SyringeEvolocumab21$19,926
PradaxaDabigatran Etexilate Mesylate22$4,193
Metoprolol Succinate300$3,134
Atorvastatin Calcium290$2,364
Rosuvastatin Calcium125$2,037
Furosemide291$1,837
Losartan Potassium205$1,616
Spironolactone189$1,545
Prasugrel Hcl14$1,371
ClopidogrelClopidogrel Bisulfate123$1,335
Metoprolol Tartrate213$1,286

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$105$153,227152 claims
Johnson & JohnsonXarelto$15$106,08990 claims
NovartisEntresto$38$38,95945 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 276 cardiovascular disease providers in Colorado.

Other cardiovascular disease in Greeley

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →